Certain Stock Options of Crinetics Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 14-JAN-2019.
January 13, 2019
Share
Certain Stock Options of Crinetics Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 14-JAN-2019. These Stock Options will be under lockup for 181 days starting from 17-JUL-2018 to 14-JAN-2019.
Details:
The company, along with its directors, executive officers and substantially all of its other stockholders and option holders, have agreed with the underwriters that for a period of 180 days, after the date of this prospectus, subject to specified exceptions, they will not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to sale of, or otherwise dispose of or transfer any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock, request or demand that we file a registration statement related to our common stock or enter into any swap or other agreement that transfers to another, in whole or in part, directly or indirectly, the economic consequence of ownership of the common stock.
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its Paltusotine, an investigational, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. It has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for CRN04894, an investigational, oral ACTH antagonist, that is in Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing's disease. Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
CRINETICS PHARMACEUTICALS, INC. 
